WO2000049135A2 - Substrate for cell growth - Google Patents
Substrate for cell growth Download PDFInfo
- Publication number
- WO2000049135A2 WO2000049135A2 PCT/GB2000/000145 GB0000145W WO0049135A2 WO 2000049135 A2 WO2000049135 A2 WO 2000049135A2 GB 0000145 W GB0000145 W GB 0000145W WO 0049135 A2 WO0049135 A2 WO 0049135A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substrate
- polysaccharide
- cell adhesion
- adhesion protein
- layer
- Prior art date
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 108
- 230000010261 cell growth Effects 0.000 title claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 120
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 120
- 230000021164 cell adhesion Effects 0.000 claims abstract description 88
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 79
- 239000005017 polysaccharide Substances 0.000 claims abstract description 79
- 239000010410 layer Substances 0.000 claims abstract description 53
- 239000000835 fiber Substances 0.000 claims abstract description 43
- 150000004676 glycans Chemical class 0.000 claims abstract description 33
- 230000015271 coagulation Effects 0.000 claims abstract description 28
- 238000005345 coagulation Methods 0.000 claims abstract description 28
- 102100037362 Fibronectin Human genes 0.000 claims abstract description 25
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 25
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 21
- 229920000615 alginic acid Polymers 0.000 claims abstract description 21
- 239000002344 surface layer Substances 0.000 claims abstract description 18
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940072056 alginate Drugs 0.000 claims abstract description 17
- 102100035140 Vitronectin Human genes 0.000 claims abstract description 4
- 108010031318 Vitronectin Proteins 0.000 claims abstract description 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 49
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 15
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 13
- 235000010413 sodium alginate Nutrition 0.000 claims description 13
- 239000000661 sodium alginate Substances 0.000 claims description 13
- 229940005550 sodium alginate Drugs 0.000 claims description 13
- 108010035532 Collagen Proteins 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- 150000001768 cations Chemical class 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000006641 stabilisation Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001718 carbodiimides Chemical class 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 230000003416 augmentation Effects 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000000416 hydrocolloid Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 2
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000003399 chemotactic effect Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000037314 wound repair Effects 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 3
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 88
- 150000004804 polysaccharides Chemical class 0.000 description 52
- 239000000243 solution Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000009987 spinning Methods 0.000 description 7
- 239000010408 film Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007380 fibre production Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000002500 ions Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/72—Chitin, chitosan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Definitions
- the present invention relates to substrates for use in cell growth and to methods of producing such substrates.
- the invention relates more particularly to substrates having cell adhesion promoting activity which may be used in various cell growth applications, e.g. wound healing and tissue engineering.
- the invention also relates to methods of preparing such substrates and their use in various cell growth applications.
- All eukaryotic, mammalian cells are substrate dependent in that they need to be attached to a surface in order to be able to grow, or secrete or divide.
- the phenotype that cells express is partly determined by their interaction with the substrate to which they are attached.
- the substrate to which mammalian cells are attached is collagen.
- All body soft (excluding blood) and hard tissues are made up of cells attached to a framework of collagen.
- Collagen is a protein that forms fibres and the fibres form matrices, these matrices may form any configuration from random to aligned.
- the collagen fibres are themselves made up of fibrils so a collagen fibre resembles a cable of aligned fibrils.
- the chemistry of the collagen fibril varies according to the tissue type and a range of collagens have been identified.
- Substrates for tissue augmentation or to act as carriers for cultured cell transfer in wound therapy are usually collagen based.
- the collagen substrate usually has to be specific to the type of cell growth required and the phenotype and status (secretory, replicatory) grown on the substrate may not turn out to be as required.
- US-A-5 610 148 entitled "Macroscopically Orientated Cell Adhesion Protein” describes the production of a fibre comprised of fibrils of a cell adhesion protein selected from fibronectin (Fn). vitronectin and von Willebrand protein that has been denatured and the polymer chains then aligned by unidirectional shear allowing aggregation and precipitation.
- Fn fibronectin
- vitronectin and von Willebrand protein that has been denatured and the polymer chains then aligned by unidirectional shear allowing aggregation and precipitation.
- These fibres are of a fibular construction not dissimilar in some respects to collagen. Cells seeded onto the fibres demonstrate directional cell growth as a result of the longitudinal orientation of the cell adhesion binding site.
- Such fibre structures require a high concentration of fibronectin or fibrinogen/fibronectin, are somewhat complicated to produce and are of relatively low strength.
- a substrate for cell growth comprising a polysaccharide and a cell adhesion protein provided at the surface of the substrate.
- Substrates in accordance with the invention have the advantage (over substrates comprised of fibrils of fibronectin or other cell adhesion protein) of being of higher strength than a substrate comprised substantially of 100% protein and are also easier to manufacture.
- the substrates of the invention may be used in a wide range of cell growth applications, e.g. wound repair, tissue repair or augmentation, or for the growth of cells in routine cell culture in vitro, in large scale cell culture, bioreactors or organ culture.
- the orientation of the cell adhesion protein is not necessarily significant and guidance of the cells during growth thereof is achieved by the physical form of the substrate.
- cell growth may occur along and/or around the fibre as determined by the presence of the cell adhesion protein.
- the cell adhesion protein preferably incorporates the RGD (Arginine, Glycuse, Aspartic acid) binding site. It is particularly preferred that the cell adhesion protein is fibronectin, vitronectin or von Willebrand protein or a fragment of such proteins incorporating this RGD binding site.
- RGD Arginine, Glycuse, Aspartic acid
- the preferred cell adhesion protein is fibronectin which may be used in the form routinely isolated from blood plasma, e.g. by cryoprecipitation.
- the fibronectin may contain fibrinogen and albumin.
- the polysaccharide and the cell adhesion protein may be uniformly distributed throughout the substrate so that the cell adhesion protein is present at the surface as a result of this distribution.
- the substrate may comprise a polysaccharide basal layer having a surface layer of a cell adhesion protein.
- the polysaccharide basal layer will for preference have a thickness of at least 60%), more preferably at least 80%) and ideally at least 90%> of the combined depth of the basal layer and cell adhesion protein layer.
- the cell adhesion protein provided as a surface layer for the polysaccharide basal layer may be an integral layer or may be a surface absorbed molecular layer.
- the surface layer of the cell adhesion protein may, depending on the method by which it is produced, be only several molecules thick or may be of somewhat greater thickness so as to form a discrete outer layer.
- the protein layer may be anything from 3-5 molecules "deep” in the case of surface adsorption to, say, 20 ⁇ m (e.g. 1-20 ⁇ m) when formed as a "coating".
- This protein layer may be an essentially amorphous network, have some crystallinity or even little or no fibril structure.
- the protein layer may be stabilised and attached to the basal (polysaccharide) layer to different degrees by different physical and/or chemical mechanisms. Examples of such attachment and stabilisation including covalent bonding, hydrogen bonding, van der Waals forces and physical entrapment.
- covalent attachment may be achieved by a carbodiimide which "couples" a carboxylic group of the polysaccharide with an amino group of a protein.
- a further possibility is the use of a melamine-formaldehyde resin.
- the degree of stability of the protein layer can be used as a mechanism to drive certain cell responses.
- the substrate may be "tailored" to ensure growth of a particular cell type and/or to provide a known degree of cell growth in a predetermined time.
- the polysaccharide layer will for preference comprise at least 50%>, more preferably at least 60%>, even more preferably at least 80%> and ideally at least 90%> polysaccharide.
- the cell adhesion protein layer will preferably comprise at least 50%>, more preferably at least 60% even more preferably at least 80%> and ideally at least 90% of cell adhesion protein.
- the cell adhesion protein layer may incorporate proteins other than cell adhesion proteins.
- Cell growth substrates in accordance with the invention may incorporate, e.g. in the polysaccharide layer, an active agent for delivery during the cell growth application.
- This agent may, for example, be deliverable by diffusion and might for example be a drug.
- Further examples of active agents include growth factors, chemotactic agents etc.
- the active agents may be free or encapsulated, for example in lipid type droplets.
- the active agent may be disposed continuously or discontinuously along, across and/or around the cell growth substrate and may be provided in different amounts at different regions of the substrate so as to establish a concentration gradient.
- Substrates in accordance with the invention may be produced by a number of methods.
- a solution containing dissolved polysaccharide and cell adhesion protein (the solution containing less of the protein than the polysaccharide) is extruded into a coagulation bath.
- the coagulation bath may incorporate, for example, di- or higher- valent cations (e.g. Ca 2+ ) which serve to effect the precipitation and also stabilise the protein layer by ion bridging.
- the polysaccharide is extended into a coagulation both which incorporates protein (containing the cell adhesion protein) as the coagulant.
- the protein coagulant may for example be an enriched blood plasma (containing a cell adhesion protein).
- a surface layer of a cell adhesion protein may be applied to a preformed polysaccharide.
- Application of the protein layer may be effected, for example, in a coating bath containing a solution of protein or by a technique such as spraying.
- Stabilisation of the surface layer may be by a carbodiimide.
- polysaccharides which may be used for the substrate include alginates, chitosan, polylysine and other polyamino acids, cationic starches, cationic derivatives of other hydrocolloids, collagen, gelatine, low-methoxyl pectin, carrageenans, chondroitin sulphate, hyaluronic acid, carboxymethyl cellulose, carboxymethyl starch, carboxymethyl guar, cellulose sulphate, dextron sulphate, gellan, xanthan, and anionic derivatives of other hydrocolloids.
- the polysaccharide is comprised of an alginate material cross-linked with calcium ions as other di- or higher valent cation capable of cross-linking alginates.
- cell growth substrates in accordance with the invention are in the form of fibres having a core (providing the basal layer) which consists of. or is rich in, the polysaccharide material and a surface at which the cell adhesion protein is provided.
- Fibres in accordance with the invention may have a diameter of 10-lOOO ⁇ m, more preferably 40-150 ⁇ m, even more preferably 40-1 OO ⁇ m, and ideally 50-80 ⁇ m.
- the fibres may be of any appropriate length.
- Such fibres may be produced by spinning a dope comprised of a solution of the polysaccharide into a coagulation bath causing precipitation of the fibres.
- the dope may also contain dissolved cell adhesion protein which is to form the surface layer with the spinning technique being such that there is preferential initial precipitation of polysaccharide in the coagulation bath followed by later precipitation of the cell adhesion protein which thus forms a protein rich outer layer of the fibre (this layer being integral with the core).
- the dope for use in this process may for example comprise (based on the total weight of the polysaccharide and cell adhesion protein) 60-95%> (preferably about 90%) by weight of the polysaccharide and 5-40%> (preferably about 10%>) by weight of the cell adhesion protein.
- the fibre produced by such a process may have a core comprised of 50-80% by weight of the polysaccharide and an outer layer comprised of 50-80%) by weight of the cell adhesion protein and 20-50%o by weight of the polysaccharide.
- fibres may be formed by a co-axial extrusion technique in which a solution of the cell adhesion protein is extruded co- axially around a (separate) solution of the polysaccharide, both solutions being spun into the same coagulation bath, whereby a fibre having a polysaccharide core and a surface layer of the cell adhesion protein is formed.
- a dope comprised of a solution of the polysaccharide (but not the cell adhesion protein) may be spun into a coagulation bath and the fibre thus formed is treated with the cell adhesion protein.
- This treatment may be effected, for example, by providing the cell adhesion protein in the coagulation bath so that the protein is adsorbed as a surface layer onto the basal polysaccharide layer. It is however more preferred that the cell adhesion protein is applied in a bath downstream of the coagulation bath.
- the conditions in the protein bath may be such as to ensure formation of a stabilised coating of the protein layer is obtained.
- the cell adhesion protein should be concentrated at the fibre surface. If the fibre is produced by co-spinning a solution of the polysaccharide and cell adhesion protein the combination of relative molecular size, hydrophilic/hydrophobic balance and relative stability can be used to cause preferential precipitation If the fibre is produced by a two-stage process then concentration of the protein at the surface may be achieved by the use of concentration of the polysaccharide and protein at each stage, first stage mixed polysaccharide and protein, second stage predominantly protein plus surface active agents and/or stabilisers.
- the protein should be stabilised at the surface and, in fact, the lower the amount of protein the more important the stabilisation becomes.
- Stabilisation may be effected by ensuring that parts of the molecular chain of the protein are embedded in the bulk polysaccharide.
- stabilisation of the protein may be by divalent cation bridges.
- carrier cation bridging will only occur within the protein species which will help to stabilise the protein at the surface.
- a fibre is produced by ejecting an aqueous solution of sodium alginate through a spinneret into a coagulation both containing Ca 2" ions.
- the fibre is then passed through a fibronectin solution (or mixed protein solution) in a coating bath (downstream of the coagulation bath) which is at a pH that will give fibronectin a net positive charge causing it to be capable of interacting with the alginic acid.
- the fibronectin can be further bound to the alginate by passing the fibre through a coagulation/stabilisation bath at a pH that favours fibronectin to become negatively charged thus favouring divalent cation bridging so as to stabilise the fibronectin on the polysaccharide.
- this bath may incorporate carbodiimide for effecting covalent bonding if the protein to the polysaccharide
- the coagulation/stabilisation bath may contain agents that modify either directly the interaction of the fibre with cells (for example through the nature of a counterion, e.g. Zm, Ag, Mn, Ce) or indirectly by influencing the surrounding environment by diffusion of an active molecular species, such as growth factors, aggregating agents, chemoattractants. surfactants, etc.
- a fibronectin coating by spraying a fibronectin solution onto the fibre. Spaying provides. Spraying provides a means of thin coating (i.e. only several molecules thick) and also a method of coating that will potentially produce a fibrillar form of the coating if the conditions of shear etc. are set correctly. These conditions may also be adjusted to give orientation of the fibril formed in relation to the substrate.
- fibres may be found in a single stage process by spinning a dope containing dissolved sodium alginate and fibronection into a solution of calcium or other divalent ions (which provide the driving force for precipitation).
- the dope is formulated such that the fibronectin is preferentially precipitated at the surface of the fibre.
- the relative amounts of the calcium alginate to the fibronectin in the dope would preferably be of the order of at least 80 parts by weight alginate and at most 20 parts fibronectin.
- the fibre would be produced under conditions that encourage the globular nature of the protein. This may be achieved by use of a pH or temperature (for the coagulation bath) that causes chains of the protein molecule to "roll-up" on themselves with a tendency to embed the ends of the chain in the fibre structure.
- a polyelectrolyte such as chitosan would be mixed with the fibronectin solution and a fibre precipitated by spinning into a sodium hydroxide bath.
- the molecular weight of the chitosan would be chosen to encourage fibre formation.
- a dope comprising a solution of chitosan (as the polysaccharide) to form a fibre which may subsequently be coated with fibronectin.
- This coating (of fibronectin) would be formed by charge interaction directly between the charged chitosan side chains and the amino acid groups of the fibronectin as well as by cationic bridging.
- the spun fibres may be subjected to stretching, washing, and/or drying operations.
- a (separate) surface treatment of the cell adhesion protein is applied after formation of the basal polysaccharide layer, it may be appropriate to effect stretching and/or washing prior to the treatment with the cell adhesion protein.
- fibres are the preferred form of the cell growth substrate in accordance with the invention, other forms are possible. Examples include sheets and strips which may be produced by forming (by a knife over roll or transfer coat or slot dye method) a thin film of a solution of the polysaccharide which is then precipitated in a coagulation bath. As in the case of fibre formation, the solution may also incorporate the cell adhesion protein to be preferentially deposited on coagulation at the surface of the polysaccharide. Alternatively the solution to be precipitated in the coagulation bath need not include the cell adhesion protein which may then be applied subsequently to the sheet or strip by spraying with a solution of the protein.
- the nature of the coating is determined by the concentration of the protein in solution, the velocity, orifice, size and direction of spray relative to the surface. Judicious adjustment of these parameters should produce undenatured but aligned molecules of active protein.
- the surface layer of the cell adhesion protein may be applied to the sheet by spraying with a solution of the protein. By spraying at high concentration and flow rate through a small orifice, protein denaturation, fibril formation and alignment can be obtained and if this is directed in parallel to a surface then this alignment will be maintained in the surface coat obtained molecular alignment of the protein will then be reflected in the alignment of cellular species grown on the substrate.
- basal polysaccharide layer is formed by a spinning or extruding a solution of sodium alginate into a bath containing calcium ions.
- Preferred sodium alginate for use in such a technique have a Guluronic acid (G) content of at least 35% by weight and a Mannuronic acid (M) content of at most 65% by weight.
- G-content is 35-70%> by weight and the M- content is 65-30%> by weight.
- M preferably also the sodium alginate has a viscosity for a 1%) solution (in water) of the sodium alginate of 30-300 cP, more preferably 40- 100 cP.
- the alginate solution to be spun or extruded into the coagulation bath should generally have a total dissolved solids content of less than 10%> by weight, more preferably in the range 5-7%.
- the amount of the cation (e.g. calcium) present in the coagulation bath (to effect precipitation of the alginate) is preferably less than 1%> by weight.
- the alginate solution (to be coagulated) to contain at least one additional polysaccharide to modify the properties of the alginate.
- the additional polysaccharide may, for example, be one having COO " groups along the polysaccharide chains, for example pectin, carboxymethyl cellulose N-, O- carboxymethyl chitosan, carrageenan, xanthan or gellan.
- the polysaccharide to the coagulated with the alginate may be one having SO 4 " groups provided along the polysaccharide chain, e.g.
- Uncharged polysaccharides may be used in conjunction with the alginate, e.g. acemannan.
- the additional polysaccharide may be one which improves the water absorbency of the alginate.
- Further disclosure of products obtained by coagulation of an alginate solution containing at least one other polysaccharide are given in WO-A-9610106 (Innovative Technologies Ltd), the disclosure of which is incorporated herein by reference.
- the surface layer of the cell adhesion protein may be continuous or discontinuous.
- the protein in the case of a fibre, may be provided continuously along and around the fibre length or as periodic repeats (e.g. of predetermined length) along the fibre length and at least partially around the circumference of the fibre, or as "stripe" which does not extend completely around the circumference and which extends continuously or discontinuously along the fibre length.
- parts of the surface of the cell growth substrate may (when used for cell growth) be positively interactive ("talking") and other parts passive (“silent") and other parts negatively interactive (“discouraging”). In cellular terms, this means that a positive surface encourages cell adhesion spreading, motility and growth whereas a passive surface (“silent”) may have a low level of interaction
- Cell growth substrates in accordance with the invention may be used in a number of forms for various cell growth applications.
- substrates in the form of fibres may be formed into a structure, e.g. random matrices (e.g. non-woven felts and fleeces), orientated matrices (fibres having some relative alignment), knitted structures (e.g. knitted cloths), braided structures (e.g. braided thread), bundled structures, and carded slivers.
- One preferred structure comprises fibres in accordance with invention laid in parallel or randomly to each other and for preference bonded to a supporting layer, e.g. a polyurethane film. This supporting layer may be adhesively coated.
- fibres to be arranged in an amorphous gel.
- a further possibility relates to fibres produced with a polysaccharide (e.g. alginate) cross-linked by a di- or higher-valent cation (e.g. calcium).
- a polysaccharide e.g. alginate
- a di- or higher-valent cation e.g. calcium
- Such fibres may (using the techniques disclosed in WO-A-9613285 (Innovative Technologies Ltd) be admixed with an aqueous solution of a hydrogel precursor material whereby the cations from the fibres cross-link the precursor material resulting in the formation of a hydrogel in which the molecules of the hydrogel precursor are cross-linked by the di- or higher-valent cations donated by the fibres.
- the admixture may incorporate a plasticiser.
- water may be removed from the hydrogel so as to provide a dehydrated form thereof containing the fibres as reinforcement.
- hydrogel precursor may for example be sodium alginate and the plasticiser may for example be glycerol, polyethylene glycol, sorbitol or a PEO/PPO polymer.
- Cell growth substrates in the form of strips or sheets may for example be rolled into tubes or other three dimensional structures.
- cell growth substrates in accordance with the invention may be used in a range of cell growth applications. If cell alignment on the surface of the substrate is important then this may be imposed by the nature of the cell and its relationship to its surface. For example, cell alignment may be determined by the size of a fibre on which the cell is grown. If cell-long alignment either across or parallel to a particular axis of the substrate is required then this can be accomplished by either exposure of the surface to flow which will produce a wall shear stress parallel to the desired orientation or to axial strain which would tend to cause the cells to lie across the axis of stress and therefore across the axis of the surface.
- the substrates may be used in wound therapy.
- a cell-growth substrate in the form of a flat sheet or film may be preferred.
- the film or sheet material may incorporate an agent to be delivered to the wound.
- parallel or random arrays of fibres with or without seeded cells may be placed on the wound either individually, in a bundled or fixed to a support which may be adhesively coated.
- a suitable support is polymeric film material particularly a breathable film (e.g. high MVTR film).
- the film may be one having an MVTR when in contact with liquid water which is at least twice that when in contact with moisture vapour (but not liquid water).
- the MVTR in contact with water vapour only may be 3000-5000 g m "2 24hr " ' (as measured by ASTM E96B) and an MVTR in the presence of liquid water (as measured by ASTM E96BW) of 8000 to 10000 g m "2 24hr "1 .
- the support may have apparatus to allow exudate transfer. Whether or not a support is used, the fibres applied to the wound may incorporate growth factors for delivery to surface cells or incorporate agents that will influence the surrounding environment, e.g. bactericides etc. Mixtures of fibres may be applied to the wound, e.g. any two of (i) fibres seeded with cells, (ii) unseeded fibres, and (iii) fibres containing an agent to be delivered to the wound.
- Cell growth substrates in accordance with the invention may be cultured with single layers of epidermal keratinocytes or dermal fibrobalasts (either of which may be of autologous or heterologous origin.)
- the substrate (with cultured cells) may be used alone or in combination with similarly cultured substrates. These substrates and cells may be used for the treatment of partial thickness wounds, e.g. donor sites and for treatment of ulcers.
- Cell growth substrates in the form of continuous fibres can be positioned in relation to a damaged organ or structure. They may be placed either singularly or in bundles during invasive or non-invasive therapy.
- cell growth substrates in the form of fibres may be provided as an injectable suspension.
- the suspension may be introduced into the body along a catheter guide system or the fibres may be formed at the site.
- Cell growth substrates in the form of fibres may be aligned parallel to tendons and seeded in situ with appropriate cells, chondrocytes, etc.
- fibres plus cell may be cultured in a laboratory and then delivered to the patient.
- the fibres may contain, or be associated with fibres constructed with hyaluronic acid or other cartilage-derived substances.
- Cell growth substrates in the form of fibres may be knitted, woven or spun into tubes to encourage cell growth to form a blood conduit.
- Damaged nerves can be repaired using fibres to link the two (separated) ends of the nerve thus providing a path along which the new nerve can grow.
- Cell growth substrates may incorporate active molecules located in the polysaccharide layer. These agents may be used to influence the fibre incorporation into the tissue. Alternatively the agent may provide a drug reservoir for the purposes topical or systemic therapy.
- the cell adhesion protein may be replaced by a blood plasma component.
- the cells and fibres were washed twice in Phosphate Buffered Saline (PBS) and then fixed using formalin solution (10% neutral buffered) for 10 minutes. The fixative was removed and the cells and fibres washed twice more in PBS. The cells were then stained with Geimsa for 10 minutes, followed by 3, five minute washes in PBS. The cells were then viewed using a Nikon Diaphot microscope and images captured using a JVC DV1 digital camcorder. The images were then downloaded to an Apple Macintosh Power PC Performa 6400/200 and analysis performed using the public domain program NIH image. For the scanning electron microscopy, fixed samples were dehydrated in 100% ethanol for a period of 2 hours.
- PBS Phosphate Buffered Saline
- the samples were then sputter coated using a Denton Vacuum desk 1.
- the samples were mounted on a stub and viewed using a Hitachi S-510 scanning electron microscope. Images are captured using the JVC camera and analysed on the Macintosh computer using NIH image.
- Bovine blood was taken and mixed in a 9:1 ratio with a 4%>w/w aqueous solution of trisodium citrate (Sigma Chemicals) as an anti-coagulant.
- the mixture was then centrifuged at lOOOrpm for 10 minutes, after which time the supernatant plasma was pipetted off, frozen at -15 to 20 °C and then thawed under refrigeration at 4°C. This caused the globular protein content of the plasma to remain precipitated and become concentrated by sedimentation at the bottom of the storage vessel.
- the supernatant from the refrigerated plasma was removed and the remaining fraction when thawed formed a plasma further enriched in globular protein concentration which may be further enriched by another freeze tha cycle.
- the plasma fraction thus isolated was used in some of the experiments outlined in the Examples below.
- Example 1 Comparative
- Calcium alginate fibres were produced by ejection at 12m/min of a 5.5%>w/w aqueous solution of sodium alginate (ex Pronova Biopolymer, having a guluronic acid content of 70%>) through a spinneret having 40,000 holes each of 70 ⁇ diameter into a coagulation bath of calcium chloride dihydrate (1.5%w/w) and the resulting fibres were washed in acetone and dried.
- the fibres were observed under a scanning electron microscope (Hitachi model S510) and were found to be about 10-20 ⁇ diameter smooth, cylindrical with few outstanding surface topographical features (see Figure 1).
- the cell adhesion properties of the fibres were then assessed using L929 mouse fibroblast cells according to the method outlined above. No cell attachment to the fibres was observed within 2 hours during which time the fibres formed a gel and then disintegrated.
- Example 3 A mixture of 5.5%w/w aqueous solution of sodium alginate (as in Example 1) with bovine blood plasma was prepared by mixing the components in a ratio of 3:2. This mixture was then used to produce fibres in the laboratory by ejection from a 1ml insulin syringe through a needle of 35 ⁇ outside diameter into a coagulation bath of calcium chloride dihydrate (1.5%w/w) and the resulting fibres were washed in acetone and dried. Fibres were observed under the scanning electron microscope (see Figure 2a). The cell adhesion properties of the fibres were then assessed using L929 mouse fibroblast cells according to the method outlined above. Within 48 hours cells had grown to confluence on the fibres (see Figure 2b), a considerable improvement of the result observed in Example 1 .
- Example 3 Comparative
- Chitosan fibres were made in the laboratory by ejecting the chitosan solution from a lml insulin syringe through a needle of 35 ⁇ outside diameter into a coagulation bath of sodium hydroxide (5%>w/w) and the resulting fibres were dried. The fibres were observed under the scanning electron microscope, the fibres were found to have a diameter of 40-100 ⁇ and to be smooth, cylindrical with few outstanding surface topographical features. The cell adhesion properties of the fibres were then assessed using L929 mouse fibroblast cells according to the method outlined above. After 48 hours, a number of cells were found to adhere to the fibres but no evidence for cell elongation and alignment was apparent (see Figure 3).
- Chitosan fibres were made in the laboratory by ejecting a solution of chitosan (as specified in Example 3) from a lml insulin syringe through a needle of 35 ⁇ outside diameter into a coagulation bath of enriched bovine blood plasma (isolated as described above) and the resulting fibres were washed in acetone and dried. The cell adhesion properties of the fibres were then assessed using L929 mouse fibroblast cells according to the method outlined above. Within 48 hours cells h ad grown to confluence (as seen from Figure 4) on the fibres, a far higher degree of cell attachment than that observed for fibres coagulated in sodium hydroxide (compare Example 3).
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21153/00A AU2115300A (en) | 1999-01-21 | 2000-01-21 | Cell growth |
DE60040648T DE60040648D1 (en) | 1999-01-21 | 2000-01-21 | CARRIER FOR CELL GROWTH |
EP00901189A EP1144592B1 (en) | 1999-01-21 | 2000-01-21 | Substrate for cell growth |
JP2000599861A JP2002536974A (en) | 1999-01-21 | 2000-01-21 | Cell proliferation |
US11/110,362 US20060051867A1 (en) | 1999-01-21 | 2005-04-20 | Cell growth |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9901272-6 | 1999-01-21 | ||
GBGB9901272.6A GB9901272D0 (en) | 1999-01-21 | 1999-01-21 | Fibres |
GB9903561-0 | 1999-02-17 | ||
GBGB9903561.0A GB9903561D0 (en) | 1999-02-17 | 1999-02-17 | Cell growth |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/110,362 Continuation US20060051867A1 (en) | 1999-01-21 | 2005-04-20 | Cell growth |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000049135A2 true WO2000049135A2 (en) | 2000-08-24 |
WO2000049135A3 WO2000049135A3 (en) | 2000-12-14 |
Family
ID=26315009
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000144 WO2000047716A2 (en) | 1999-01-21 | 2000-01-21 | Fibres for culturing eukaryotic cells |
PCT/GB2000/000145 WO2000049135A2 (en) | 1999-01-21 | 2000-01-21 | Substrate for cell growth |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000144 WO2000047716A2 (en) | 1999-01-21 | 2000-01-21 | Fibres for culturing eukaryotic cells |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060051867A1 (en) |
EP (2) | EP1144592B1 (en) |
JP (2) | JP2002536974A (en) |
AT (1) | ATE412733T1 (en) |
AU (2) | AU2115200A (en) |
DE (1) | DE60040648D1 (en) |
ES (1) | ES2315223T3 (en) |
WO (2) | WO2000047716A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002142752A (en) * | 2000-11-13 | 2002-05-21 | Asahi Techno Glass Corp | Collagen-coated cell culture vessel and method for producing the same |
JP2002142751A (en) * | 2000-11-13 | 2002-05-21 | Asahi Techno Glass Corp | Collagen-coated cell culture vessel and culture member |
US6589199B1 (en) * | 1997-08-28 | 2003-07-08 | Boston Scientific Corporation | System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber |
WO2007144389A2 (en) * | 2006-06-16 | 2007-12-21 | Fmc Biopolymer As | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof |
US8080418B2 (en) | 2007-03-09 | 2011-12-20 | Corning Incorporated | Method of making a three dimensional cell culture matrix |
EP2452703A3 (en) * | 2010-11-12 | 2014-10-01 | Biotronik AG | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functionalized RGD peptidomimetics |
US8961592B2 (en) | 2010-11-12 | 2015-02-24 | Biotronik Ag | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functional-ized RGD peptidomimetics |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596296B1 (en) | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US7033603B2 (en) | 1999-08-06 | 2006-04-25 | Board Of Regents The University Of Texas | Drug releasing biodegradable fiber for delivery of therapeutics |
EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
WO2009015186A2 (en) * | 2007-07-23 | 2009-01-29 | Drexel University | Articles and methods for repairing damaged nervous tissue |
TWI414328B (en) * | 2008-09-18 | 2013-11-11 | Nat Health Research Institutes | Implantable nerve regeneration conduit |
WO2011038053A1 (en) * | 2009-09-25 | 2011-03-31 | Armark Authentication Technologies, Llc | Tissue fiber scaffold and method for making |
CN102499994A (en) * | 2011-11-04 | 2012-06-20 | 无锡中科光远生物材料有限公司 | Nervous tissue engineering fibrous membrane and preparation method |
US20140017263A1 (en) | 2012-06-28 | 2014-01-16 | Clemson University | Delivery Agents for Targeted Treatment of Elastin Degradation |
CN103966097A (en) * | 2014-05-26 | 2014-08-06 | 扬州大学 | Preparation method and application of carboxymethyl cellulose-coated RGD short peptide-coupled cell culture plate |
CN103966096A (en) * | 2014-05-26 | 2014-08-06 | 扬州大学 | Cell culture plate and preparation method and application thereof |
CN106435815B (en) * | 2016-09-20 | 2018-07-13 | 大连工业大学 | Chemical crosslinking modified fibroin albumen/alginate composite fiber and preparation method thereof |
CN111996616B (en) * | 2020-08-20 | 2021-09-28 | 江南大学 | Sodium alginate/polylysine self-assembled fiber with controllable size |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010106A1 (en) * | 1994-09-29 | 1996-04-04 | Innovative Technologies Limited | Fibres |
WO1998012228A1 (en) * | 1996-09-19 | 1998-03-26 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59192709A (en) * | 1983-04-15 | 1984-11-01 | Toray Ind Inc | Fiber having surface groove and uneven thickness, and manufacture thereof |
JPH01309682A (en) * | 1988-06-03 | 1989-12-14 | Sanyo Chem Ind Ltd | Substrate for animal cell culture |
US4948575A (en) * | 1989-01-24 | 1990-08-14 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
GB9403135D0 (en) * | 1994-02-18 | 1994-04-06 | Univ Glasgow | Wound healing device |
US5610145A (en) * | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
US5855608A (en) * | 1994-05-13 | 1999-01-05 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
GB9515327D0 (en) * | 1995-07-26 | 1995-09-20 | Univ London | Site-directed bone formation |
JP2822174B2 (en) * | 1996-03-01 | 1998-11-11 | オーミケンシ株式会社 | Method for producing chitin chitosan fiber and structure |
-
2000
- 2000-01-21 AT AT00901189T patent/ATE412733T1/en not_active IP Right Cessation
- 2000-01-21 DE DE60040648T patent/DE60040648D1/en not_active Expired - Lifetime
- 2000-01-21 ES ES00901189T patent/ES2315223T3/en not_active Expired - Lifetime
- 2000-01-21 EP EP00901189A patent/EP1144592B1/en not_active Revoked
- 2000-01-21 WO PCT/GB2000/000144 patent/WO2000047716A2/en not_active Application Discontinuation
- 2000-01-21 WO PCT/GB2000/000145 patent/WO2000049135A2/en active Application Filing
- 2000-01-21 JP JP2000599861A patent/JP2002536974A/en active Pending
- 2000-01-21 AU AU21152/00A patent/AU2115200A/en not_active Abandoned
- 2000-01-21 JP JP2000598616A patent/JP2002536011A/en active Pending
- 2000-01-21 AU AU21153/00A patent/AU2115300A/en not_active Abandoned
- 2000-01-21 EP EP00901188A patent/EP1147175A2/en not_active Withdrawn
-
2005
- 2005-04-20 US US11/110,362 patent/US20060051867A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010106A1 (en) * | 1994-09-29 | 1996-04-04 | Innovative Technologies Limited | Fibres |
WO1998012228A1 (en) * | 1996-09-19 | 1998-03-26 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch, Week 199005 Derwent Publications Ltd., London, GB; Class A96, AN 1990-032925 XP002147316 & JP 01 309682 A (SANYO CHEM IND LTD), 14 December 1989 (1989-12-14) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589199B1 (en) * | 1997-08-28 | 2003-07-08 | Boston Scientific Corporation | System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber |
JP2002142752A (en) * | 2000-11-13 | 2002-05-21 | Asahi Techno Glass Corp | Collagen-coated cell culture vessel and method for producing the same |
JP2002142751A (en) * | 2000-11-13 | 2002-05-21 | Asahi Techno Glass Corp | Collagen-coated cell culture vessel and culture member |
WO2007144389A2 (en) * | 2006-06-16 | 2007-12-21 | Fmc Biopolymer As | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof |
WO2007144389A3 (en) * | 2006-06-16 | 2008-02-14 | Fmc Biopolymer As | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof |
US8168215B2 (en) | 2006-06-16 | 2012-05-01 | Fmc Biopolymer As | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof |
US8080418B2 (en) | 2007-03-09 | 2011-12-20 | Corning Incorporated | Method of making a three dimensional cell culture matrix |
EP2452703A3 (en) * | 2010-11-12 | 2014-10-01 | Biotronik AG | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functionalized RGD peptidomimetics |
EP2452702A3 (en) * | 2010-11-12 | 2014-10-01 | Biotronik AG | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functionalized RGD peptidomimetics |
US8961592B2 (en) | 2010-11-12 | 2015-02-24 | Biotronik Ag | Functionalized RGD peptidomimetics and their manufacture, and implant having a coating containing such functional-ized RGD peptidomimetics |
Also Published As
Publication number | Publication date |
---|---|
JP2002536011A (en) | 2002-10-29 |
EP1144592A2 (en) | 2001-10-17 |
JP2002536974A (en) | 2002-11-05 |
AU2115200A (en) | 2000-08-29 |
EP1144592B1 (en) | 2008-10-29 |
WO2000047716A3 (en) | 2000-12-14 |
ES2315223T3 (en) | 2009-04-01 |
EP1147175A2 (en) | 2001-10-24 |
ATE412733T1 (en) | 2008-11-15 |
WO2000049135A3 (en) | 2000-12-14 |
US20060051867A1 (en) | 2006-03-09 |
AU2115300A (en) | 2000-09-04 |
DE60040648D1 (en) | 2008-12-11 |
WO2000047716A2 (en) | 2000-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060051867A1 (en) | Cell growth | |
Raus et al. | Alginate and alginate composites for biomedical applications | |
Rahmati et al. | Electrospinning for tissue engineering applications | |
Zhang et al. | Biodegradable polymers as the pivotal player in the design of tissue engineering scaffolds | |
Supaphol et al. | Electrospinning of biocompatible polymers and their potentials in biomedical applications | |
Liu et al. | Composite poly (lactic acid)/chitosan nanofibrous scaffolds for cardiac tissue engineering | |
Gu et al. | Fabrication of sonicated chitosan nanofiber mat with enlarged porosity for use as hemostatic materials | |
Beachley et al. | Polymer nanofibrous structures: Fabrication, biofunctionalization, and cell interactions | |
Mao et al. | The properties of chitosan–gelatin membranes and scaffolds modified with hyaluronic acid by different methods | |
US9192655B2 (en) | System and method for a hydrogel and hydrogel composite for cartilage repair applications | |
Petrenko et al. | Coupling of gelatin to inner surfaces of pore walls in spongy alginate-based scaffolds facilitates the adhesion, growth and differentiation of human bone marrow mesenchymal stromal cells | |
US10729804B2 (en) | Nanofibrillar cellulose composition | |
Lukanina et al. | Multi-hierarchical tissue-engineering ECM-like scaffolds based on cellulose acetate with collagen and chitosan fillers | |
Chen et al. | Three-dimensional porous gas-foamed electrospun nanofiber scaffold for cartilage regeneration | |
McCullen et al. | Nanofibrous composites for tissue engineering applications | |
Datta et al. | Importance of alginate bioink for 3D bioprinting in tissue engineering and regenerative medicine | |
Ashammakhi et al. | Advancing tissue engineering by using electrospun nanofibers | |
JPH10503098A (en) | Compositions and methods for bioartificial extracellular matrices | |
Wang et al. | Bacterial cellulose: a natural nanomaterial for biomedical applications | |
ter Horst et al. | Natural polymers: Biomaterials for skin scaffolds | |
Lin et al. | Fibrous hydrogel scaffolds with cells embedded in the fibers as a potential tissue scaffold for skin repair | |
Rodriguez-Velazquez et al. | Polysaccharide-based nanobiomaterials as controlled release systems for tissue engineering applications | |
Zhang et al. | Organic solvent-free preparation of chitosan nanofibers with high specific surface charge and their application in biomaterials | |
Liu et al. | Advances in hydrogels for stem cell therapy: regulation mechanisms and tissue engineering applications | |
Arca et al. | Chitosan based systems for tissue engineering part II: soft tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 599861 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000901189 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000901189 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09889715 Country of ref document: US |